Activity Title: 2019 Fall Clinical Lipid Update: Top 10 Takeaways
During this activity, Dr. Nihar Desai and Dr. Alan Brown discuss their top 10 takeaway messages from the National Lipid Association’s 2019 Fall Clinical Lipid Update. Tune in to learn more about the use of coronary calcium scoring and advances in lipid laboratory measurements.
Internet Enduring Activity
This activity is designed to meet the needs of lipidologists, internists, endocrinologists, registered nurses, nurse practitioners, advance practice registered nurses and those with an interest in lipid management.
At the Conclusion of this activity, participants should be able to:
- Discuss the clinical recommendations for the use of coronary calcium scoring.
- Discuss the use of lipid testing for the management of dyslipidemia and ASCVD risk.
CRITERIA FOR SUCCESS
Statements of credit will be awarded based on the participant’s participation in the activity and post-assessment with a score of 50% or greater and submission of the activity evaluation form. Partial credit may be awarded for ACPE credit. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme. The deadline to claim credit is May 8, 2020.
This activity is supported by educational funding provided by Aegerion Pharmaceuticals, Inc. and Amarin Pharma Inc.
CME credit provided by the National Lipid Association
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation Statement
The National Lipid Association designates this internet enduring activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.
NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.
The maximum number of hours awarded for this CE activity is 1.0 contact hours.
This continuing education activity offered 0.8 pharmacotherapy contact hours.
Director, Division of Cardiology
Advocate Heart Institute
Advocate Lutheran General Hospital
Co-Director, Cardiology Service Line
Advocate Medical Group
Yale School of Medicine
DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCTS
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.
Amarin, Amgen, The Medicines Company, Regeneron, Sanofi
Amarin, Amgen, Regeneron, Sanofi
|Desai, Nihar||Consultant||Amgen, Boehringer Ingelheim, Cytokinetics, Novartis, Relypsa|
|NLA||N/A||NLA staff has nothing to disclose.|
|Elkins, Casey, DNP||N/A||Nothing to disclose.|
This page was last updated: May 07, 2020